^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Glioblastoma

    Related cancers:
    1d
    Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    temozolomide
    1d
    FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT) (clinicaltrials.gov)
    P=N/A, N=11, Completed, Sunnybrook Health Sciences Centre | Recruiting --> Completed
    Trial completion
    1d
    Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma (clinicaltrials.gov)
    P2, N=33, Suspended, Weill Medical College of Cornell University | Trial completion date: Dec 2025 --> Jun 2026 | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    metformin • paxalisib (GDC-0084)
    1d
    Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment. (PubMed, Nat Commun)
    This platform comprises GIC-targeting exosomes that carry siRNA for Notch1 and mitoxantrone to reduce the stemness of GICs and kill residual GICs and glioma cells, respectively, and an immune activator (interleukin-12), which can remodel the immunosuppressive tumor microenvironment, ultimately suppressing postoperative GBM relapse. Our work provides a perspective into the effective inhibition of postresection recurrence of GBM.
    Journal
    |
    NOTCH1 (Notch 1)
    |
    mitoxantrone
    1d
    NRG-BN001: Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=606, Active, not recruiting, NRG Oncology | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial primary completion date
    |
    temozolomide
    1d
    Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab)
    2d
    BRIDGES: Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care (clinicaltrials.gov)
    P3, N=766, Recruiting, GT Medical Technologies, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    temozolomide
    2d
    ONC206-001: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (clinicaltrials.gov)
    P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date • First-in-human
    |
    JZP3507
    2d
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    2d
    FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma (clinicaltrials.gov)
    P=N/A, N=7, Completed, Jonsson Comprehensive Cancer Center | N=50 --> 7 | Trial completion date: Aug 2026 --> Jan 2025 | Trial primary completion date: Aug 2025 --> Jan 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    3d
    ReVoGlio: Vortioxetine for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, University of Zurich
    New P2 trial
    |
    temozolomide
    3d
    Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. (clinicaltrials.gov)
    P1, N=18, Recruiting, Henry Ford Health System | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Jan 2027
    Trial completion date • Trial primary completion date